SELLAS Life Sciences Group Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.20next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| SLS009 Phase 2 Topline Data Release | 31 Dec 2026 |
Monitoring Framework
Key Performance Indicators
REGAL Trial Event Count Quarterly78
Cash and Cash Equivalents Quarterly107.1MTarget: Sufficient to fund operations for at least twelve months
SLS009 Phase 2 Trial Enrollment Quarterly
Watch Items
- REGAL Trial 80th Event AnnouncementTrigger: 80 events (deaths) recorded by the CROAction: Initiate database lock, blinded data review, statistical analysis, and unblinding for topline data disclosure.
- HKIAC Arbitration Ruling against 3D MedicinesTrigger: Arbitration decision expected between July and September 2026Action: Assess impact on cash position regarding the ~$13 million in disputed milestone payments.
- SLS009 Phase 2 Topline Data ReadoutTrigger: Topline data release in Q4 2026Action: Evaluate efficacy and safety of SLS009 in newly diagnosed first-line AML patients.
Research as of 20 Jun 2026